Erin is an award-winning journalist focusing on digital health technologies, venture capital, and Big Tech at Axios. Before Axios, Erin worked at STAT News, Business Insider, Newsweek, Popular Science and Scientific American.

Dr. Ng is a Partner and Managing Director with TPG Life Science Innovations based in San Francisco.  Prior to joining TPG in 2021, Dr. Ng was a Managing Director at Vertex Ventures HC, a global healthcare and life sciences venture fund, where she co-headed the investment team and led deals across different therapeutic areas in life sciences.  Dr. Ng has served on the board of directors for several promising life sciences companies including, Bicycle Therapeutics PLC (NASDAQ: BCYC), Boundless Bio, Obsidian Therapeutics, 28-7 Therapeutics, and a board observer to Visterra (acquired by Otsuka Pharmaceutical). She is also a mentor to the Women in Bio Boardroom Ready Program.  Dr. Ng holds a PhD in Cancer Molecular Biology from the National University of Singapore, where she was the recipient of the prestigious NGS, Integrative Sciences and Technology, PhD scholarship.

Jonathan Norris is a managing director for business development in SVB's Healthcare practice. Norris oversees business development efforts for banking and lending opportunities as well as spearheading strategic relationships with many healthcare venture capital firms. He also helps SVB Capital through sourcing and advising on limited partnership allocations.

In addition, he speaks at major investor and industry conferences and authors widely cited analyses of healthcare venture capital trends. Norris has more than nineteen years of banking experience working with healthcare companies and venture capital firms.

Norris earned a bachelor's degree in business administration from the University of California, Riverside and a juris doctorate from Santa Clara University.

Julie Yoo is a General Partner at Andreessen Horowitz where she leads investments in healthcare technology, with a focus on companies that are modernizing how we access, pay for, and experience the healthcare system. 

Prior to joining a16z, Julie was the co-founder, Chief Product Officer, and Board Director at Kyruus, a venture-backed healthtech company recognized as a market leader in patient access. Julie led product management, engineering, and sales and marketing for the company, and helped scale the business to reach 20M patients and over 225,000 healthcare providers across the U.S.

Julie was previously VP of Product at Generation Health, and was with the company from its inception through acquisition by CVS Health. Julie was also a Product Manager at Knome, the world's first whole genome sequencing service for private individuals. Julie’s tech career began as an early member of the software engineering team at Endeca Technologies, which was acquired by Oracle. 

Julie studied computer science and pre-medicine as an undergrad at MIT and obtained an MS in genomics from Harvard-MIT HST and an MBA from MIT Sloan. Julie is a Young Global Leader with the World Economic Forum and has been recognized through numerous awards and honors from Becker’s Hospital Review, Health Data Management, MedTech Boston, and Rock Health.

Julie serves on a number of portfolio company boards, including AKASA, Bayesian Health, Firefly Health, Patina, Ribbon Health, Season Health, Sprinter Health, Tomorrow Health, Turquoise Health and Zus Health.